<SEC-DOCUMENT>0001193125-16-699650.txt : 20160901
<SEC-HEADER>0001193125-16-699650.hdr.sgml : 20160901
<ACCEPTANCE-DATETIME>20160901162402
ACCESSION NUMBER:		0001193125-16-699650
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160831
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160901
DATE AS OF CHANGE:		20160901

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MYRIAD GENETICS INC
		CENTRAL INDEX KEY:			0000899923
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				870494517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26642
		FILM NUMBER:		161866039

	BUSINESS ADDRESS:	
		STREET 1:		320 WAKARA WAY
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84108
		BUSINESS PHONE:		801-584-3600

	MAIL ADDRESS:	
		STREET 1:		320 WAKARA WAY
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84108
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d219216d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): August&nbsp;31, 2016 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>MYRIAD GENETICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>0-26642</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>87-0494517</B></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>320 Wakara Way </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Salt Lake City, Utah 84108 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (801)&nbsp;584-3600 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
name or former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see </I>General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;2.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Completion of Acquisition or Disposition of Assets </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;31, 2016, Myriad
Genetics, Inc. (&#147;Myriad&#148;) completed its acquisition of Assurex Health, Inc. (&#147;Assurex&#148;), in accordance with the terms of the previously announced Agreement and Plan of Merger (as amended, the &#147;Merger Agreement&#148;), dated
August&nbsp;3, 2016, by and among Myriad, Myriad Merger Sub, Inc., a wholly owned subsidiary of the Company (&#147;Merger Subsidiary&#148;), Assurex, and Fortis Advisors LLC, as the representative of the securityholders of Assurex. Pursuant to the
terms of the Merger Agreement, Merger Subsidiary was merged with and into Assurex, with Assurex continuing as the surviving corporation and wholly owned subsidiary of Myriad (the &#147;Merger&#148;). </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;2.03</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Creation of a Direct Financial Obligation of a Registrant </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;31, 2016,
Myriad entered into a Credit Agreement (the &#147;Credit Agreement&#148;), by and among Myriad, as borrower, the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as Administrative Agent (the &#147;Agent&#148;). Pursuant to the
Credit Agreement, Myriad borrowed term loans in an aggregate principal amount of $200.0 million (the &#147;Term Loans&#148;). The Term Loans mature on August&nbsp;31, 2017 (the &#147;Maturity Date&#148;). There shall be no scheduled principal
payments of the Term Loan prior to the Maturity Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proceeds of the Term Loans were used to (i)&nbsp;finance the acquisition of
Assurex, (ii)&nbsp;refinance certain existing indebtedness of Assurex and its subsidiaries, (iii)&nbsp;pay fees, commissions, transactions costs and expenses incurred in connection with the foregoing, and (iv)&nbsp;for working capital and other
general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Credit Agreement contains customary loan terms, interest rates, and representations and warranties and
usual and customary affirmative and negative covenants, in each case, subject to customary limitations, exceptions and exclusions. The Credit Agreement also contains certain customary events of default. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Agent and its affiliates have various relationships with Myriad and its subsidiaries involving the provision of financial services, such
as investment banking, commercial banking, advisory, paying agent services and escrow services for which they receive customary fees and may do so in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information contained above under Item&nbsp;2.01 is incorporated herein by reference. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Events. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;1, 2016, Myriad issued a press release announcing the
completion of the Merger. The press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Statement Regarding
Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Exhibit 99.1 to this Current Report on Form&nbsp;8-K includes &#147;forward-looking statements&#148; as
defined in the Private Securities Litigation Reform Act of 1995.&nbsp;These forward-looking statements reflect current views about future events.&nbsp;Investors should not rely on forward-looking statements because actual results may differ
materially from those predicted as a result of a number of potential risks and uncertainties.&nbsp;These potential risks and uncertainties include, but are not limited to: the possibility that the expected benefits related to the Merger may not
materialize as expected; the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to
transition from our existing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product portfolio to our new tests; risks related to changes in the governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at
comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic
tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to
successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on
satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements
or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new
technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about the
potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to
the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the
Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed
under the heading &#147;Risk Factors&#148; contained in Item&nbsp;1A of our most recent Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to
time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.&nbsp;All information in the exhibits is as of the date of the exhibits, and Myriad undertakes no duty to update this information unless required by law. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements of Business Acquired</B>. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The financial statements required by
Item&nbsp;9.01(a) will be filed by amendment no later than 71 calendar days after the date this Current Report on Form 8-K must be filed. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"><B>Pro Forma Financial Information</B>. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The pro forma financial information required by
Item&nbsp;9.01(b) will be filed by amendment no later than 71 calendar days after the date this Current Report on Form 8-K must be filed. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"><B>Exhibits</B>. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:26.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release issued by Myriad on September 1, 2016.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>MYRIAD GENETICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: August&nbsp;31, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ R. Bryan Riggsbee</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">R. Bryan Riggsbee</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B></B>Executive Vice President, Chief Financial Officer<B></B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>EXHIBIT INDEX</U> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Exhibit</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:26.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release issued by Myriad on September 1, 2016.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 5 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d219216dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g219216g88m02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="18%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Media Contact:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Ron Rogers</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Investor Contact:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Scott Gleason</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(908) 285-0248</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(801) 584-1143</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>rrogers@myriad.com</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>sgleason@myriad.com</U></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Myriad Genetics Completes Acquisition of Assurex Health </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SALT LAKE CITY, Utah, September 1, 2016 </B>&#150; Myriad Genetics, Inc. (NASDAQ: MYGN) a global leader in personalized medicine, announced today that it
has completed its acquisition of Assurex Health effective August 31, 2016. Assurex Health, which is based in Mason, Ohio, is an informatics-based precision medicine company providing treatment decision support to healthcare providers for mental
health patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;We are exceptionally pleased to close the Assurex Health acquisition as GeneSight<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> becomes our second largest product, with an outstanding growth trajectory, substantial current market potential, and the opportunity for expanded indications,&#148; said Mark C. Capone, president
and CEO, Myriad Genetics. &#147;This acquisition is an excellent strategic fit since it leverages our existing preventive care business unit with the addition of a product that has a market potential of $3 billion in this channel.&nbsp;The
acquisition has the added strategic benefit of establishing the foundation for our neuroscience business where GeneSight has a market potential of over $2 billion and the ability to leverage this sales channel for future pipeline products.&#148;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To fund the transaction, Myriad entered into a credit agreement with JP Morgan Chase Bank for an aggregate principal amount of $200
million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Myriad Genetics </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide
with pioneering molecular diagnostics.&nbsp;Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression and guide treatment
decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.&nbsp;Myriad is focused on three strategic imperatives:&nbsp;transitioning and expanding its hereditary
cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the
Company&#146;s website: <U>www.myriad.com</U>. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Myriad, the Myriad logo, BART, BRAC<I>Analysis</I>, Colaris, Colaris AP, EndoPredict, myPath,
myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the
United States and foreign countries. MYGN-F, MYGN-G </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safe Harbor Statement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This press release contains &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995,
including statements relating to the GeneSight<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> test becoming the Company&#146;s second largest product, and having an outstanding growth trajectory, substantial current market potential, and
the opportunity for expanded indications; the strategic fit of the acquisition of Assurex Health as leveraging the Company&#146;s existing preventive care business unit; the market potential of the Company&#146;s preventive care business unit
exceeding $3 billion; the GeneSight product providing the foundation for a neuroscience business unit; the GeneSight product having over $2 billion in market potential and being a channel for future pipeline products; and the Company&#146;s
strategic directives under the caption &#147;About Myriad Genetics.&#148; These &#147;forward-looking statements&#148; are based on management&#146;s current expectations of future events and are subject to a number of risks and uncertainties that
could cause actual results to differ materially and adversely from those described or implied in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic
tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests; risks related to changes in the
governmental or private insurers&#146; reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new
competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not
successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our
molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities;
risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory
terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire, including but not limited to our acquisition of a healthcare clinic in Germany; risks
related to our projections about the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of
patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United
States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and
internationally; and other factors discussed under the heading &#147;Risk Factors&#148; contained in Item 1A of our Annual report on Form 10-K for the fiscal year ended June 30, 2016, which has been filed with the Securities and Exchange Commission,
as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g219216g88m02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g219216g88m02.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@!* "@ H IZI:/?:;/;)<SVS2+@2P-M=?H>U.+L[
MB:YE8I^'M3FU"QQ=0&VNH6*20M*'=<="V/4<U4X\KT%!MK71FQ4%!0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 M !0 4 % !0 4 % !0 4 %
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M0 4 +0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M3_Z[+_*JEN3'8]#J2A: "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MK5':^$]=.OZ!!>.H6;)20#IN'I4O1E+5&+XS\6W5A=Q:-HZ>9J,^ 2!G9GH
M/6A*^K$W;1&?;_#O4[^/S]7\07 N6Y*H2P7\2:?-;87+W9!>6OB/P.IN%O7U
M/23\LBOG* ]^>GUHT8:Q+7PF.=/U,^LR_P J);A'8]$J2A: "@ H * "@ H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M(S:]=QXAL8E(7J V,*/SR:UK6HTN1=3.@_;UO:/H>UUYQZ1YMHG_ "5_5?\
M=?\ DM4_A)7Q'I-24>;^/_\ D</#W^\/_0Q51V9,MT=7XQM9[SPIJ$-NI:4Q
MY"CJ<')%2M&4]CE/A_XHT>ST,:=>3I:3QN23)P'R>N?6JDG>Y,9*UB[XK\7V
M=SITVE:-*+V\N4*_NN51>Y)^E"5MQMWT0OPL(_X1B8#M<-_(4I;A'8R_%=E>
M>&/%<?B:RB,MNY_?*.QZ$'V([^M-:JPGH[HZO3_'&@7]L)?[1B@;',<QVLM*
MS0[HPO$WC>&]@?2/#Y:[N[@%#)&/E0=\>M-1ZL'+HC/^'5R]EX=U>:/&])4
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M;>&M O-8O$E>WM$WNL0!<C.. 2!W]:B<U!7?E^+L5&+D[+^K'F7_  T=X/\
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M^B?8K^R((N[9'-I<J>AC9AU QD$D_3D"U:4>9:=+/\_Z\B7>,K/9Z_\  ?\
M7_!QG\9^*/$VLZA8^!].TXVFFRF&?4-4=Q%)(.J(J<\>O3Z<9B'-**J='MW?
MGZ?UW14K1ER=>OD7?#7C+57\2OX4\6:=!9:UY1G@FM'+6]U&"<E,\J1Z'G@G
MCI51Y9IN.ZW7Z_U_G:)7A))[/9_I_7^5^XI%"-]V@-CG=,L_[#UB[@ N9+:\
M;S_M-Q."HD)QY:CJ/6M)/FBO(SBN637<Z*LS0* "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H *  4 +0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Y?\??\ DF;_ /7Y#_,U,?\
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M?(L>-O!OAW2+>RL-<\7^,=4>_G6.#3UU!)GE;/#;&4# />J@[U8Q6^_IYO\
MK]12?+!R>WY^7]?Y&W\0$\OXC?#= 2=MU,,GK]U**3OB9/\ NO\ )BDN7#67
M\T3E-'\.Q7/Q7\6Z/J7B;6]#O;FZ^U6B6-[]G%U&Q8^AW$ C]?0XF@KT;+>+
M=U^OSZ_(JL[54^C2U]-/^&^9K:IX5\.Z=XU\/:5?>*/%FLZJ;E;BWMGO4G6
MJ<^9(&4;5XZCG .*NC+]Y[NZ3U[>7S_ROT(JJU.TMGI_7]?J:']N>+/&7CW7
M=$T;Q#;^';;1B$VFS2XFN"<?,5?HON,=1USQG23G3=1OK:WIW]?ZVUNHU&:I
MKM>_W?E_6^G)BW2R^/WAFU?Q/=:]J$:R?;))G&R*0J^41%XC'?:"<5>&:<Y\
MJTMOY]=>W;MJB:Z:IQOO=?==6_KKN=+J&@>%?&WC_6(]/OM5\.^+=.4I)/;R
MB(S@K@2  DLH&,XVD@C/45%.+<'.#LKV:^?Z_GKZW-I2C&:[-/\ 3U_KH3^$
M-5\2:+\2)?!&J:_'XAM8[ 3BY\H)-;D8&U\$G)S_ !$DY4Y&35+]]3GI:W7^
MOZT?RB:=-P=]^GWLY+X:>$XK]]8T*]\6^(=(UFQO)/,L;+4/(5TX_>!<'.>Y
M'MZBG#WJ,)+M9KMY?UUN55=J\[]7=>=_Z^XZ72M \.V?Q8T^S3Q#XFUO6]/A
M>8M<W:3PVRD%2LA(!4G/0>HS3I2OSN/:S?SV]5_GV9%5648RZO;\;_U_D>N5
M)17OGO([.1K""&>Z&-D<\QB0\\Y8*Q'&?X3_ %H PYG\4W&P3>'-"EV,'7?J
MLAVL.A&;;@^]--K832>Y)]K\7_\ 0"T7_P &\O\ \C4AA]K\7_\ 0"T;_P &
M\O\ \C4 'VOQ?_T M&_\&\O_ ,C4 'VOQ?\ ] +1O_!O+_\ (U !]K\7_P#0
M"T;_ ,&\O_R-0 ?:_%__ $ M&_\ !O+_ /(U !]K\7_] +1O_!O+_P#(U !]
MK\7_ /0"T;_P;R__ "-0 ?:_%_\ T M&_P#!O+_\C4 'VOQ?_P! +1O_  ;R
M_P#R-0 ?:_%__0"T;_P;R_\ R-0 ?:_%_P#T M&_\&\O_P C4 'VOQ?_ - +
M1O\ P;R__(U !]K\7_\ 0"T;_P &\O\ \C4 'VOQ?_T M&_\&\O_ ,C4 'VO
MQ?\ ] +1O_!O+_\ (U !]K\7_P#0"T;_ ,&\O_R-0 ?:_%__ $ M&_\ !O+_
M /(U !]K\7_] +1O_!O+_P#(U !]K\7_ /0"T;_P;R__ "-0 ?:_%_\ T M&
M_P#!O+_\C4 'VOQ?_P! +1O_  ;R_P#R-0 ?:_%__0"T;_P;R_\ R-0 ?;/%
M_P#T M&_\&\O_P C4 'VSQA_T M&_P#!O+_\C4 'VSQA_P! +1O_  ;R_P#R
M-0 ?;/&'_0"T;_P;R_\ R-0 ?;/&'_0"T;_P;R__ "-0 ?;/&'_0"T;_ ,&\
MO_R-0 ?;/&'_ $ M&_\ !O+_ /(U !]L\8?] +1O_!O+_P#(U !]L\8?] +1
MO_!O+_\ (U !]L\8?] +1O\ P;R__(U !]L\8?\ 0"T;_P &\O\ \C4 'VSQ
MA_T M&_\&\O_ ,C4 'VSQA_T M&_\&\O_P C4 'VSQA_T M&_P#!O+_\C4 '
MVSQA_P! +1O_  ;R_P#R-0 ?;/&'_0"T;_P;R_\ R-0 ?;/&'_0"T;_P;R__
M "-0 ?;/&'_0"T;_ ,&\O_R-0 ?;/&'_ $ M&_\ !O+_ /(U !]L\8?] +1O
M_!O+_P#(U !]L\8?] +1O_!O+_\ (U !]L\8?] +1O\ P;R__(U !]L\8?\
M0"T;_P &\O\ \C4 'VSQA_T M&_\&\O_ ,C4 'VSQA_T M&_\&\O_P C4 'V
MSQA_T M&_P#!O+_\C4 'VSQA_P! +1O_  ;R_P#R-0 ?;/&'_0"T;_P;R_\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
# __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
